Add Yahoo as a preferred source to see more of our stories on Google. Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 ...

BRONCHIECTASIS may silently increase risk of non-tuberculous mycobacteria infection, according to new genetic evidence.

Panelists discuss how the heterogeneity of bronchiectasis requires precise phenotyping and a treatable traits approach to address varying symptom profiles, from cough-predominant to shortness of ...

If you have non-cystic fibrosis bronchiectasis, you’re likely an expert on the “lung side” of the disease — the stubborn mucus, the nagging cough, and the constant threat of a flare-up. But by causing ...

Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under the ...

Please provide your email address to receive an email when new articles are posted on . Indigenous ethnicity and new abnormal auscultatory signs raised the odds for symptom resolution after antibiotic ...

Panelists discuss how future bronchiectasis research will focus on precision medicine, identify treatable traits, and expand networks of Centers of Excellence to provide advanced care and clinical ...

Bronchiectasis was associated with an increased mortality risk in current and former smokers even if they did not meet the spirometric criteria for chronic obstructive pulmonary disease (COPD), an ...

This activity is provided by National Jewish Health. Bronchiectasis is a complex and increasingly prevalent condition often overlooked in clinical practice, with frequent overlap with other ...

The presence of a positive fungal culture in patients with bronchiectasis does not appear to correlate with disease severity or any increased risk of an adverse outcome, according to data pulled from ...

A Prescription Drug User Fee Act target date of August 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...